Travere Therapeutics Inc (TVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.86B
Last updated: Nov 17, 2026 at 11:06 AM ET
Travere Therapeutics Inc (TVTX) Valuation Multiples
Travere Therapeutics (TVTX) trades at 7.2x sales and 208.2x book value. Its P/S of 7.2x is above its 5-year median of 6.6x. Its forward P/E is 25.1x.
Current Multiples
Its free cash flow yield is 1.9%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 25.1x |
| Price to sales | 7.2x |
| Price to book | 208.2x |
| Price to FCF | 51.6x |
| EV/FCF | 56.9x |
| PEG | N/A |
| FCF yield | 1.9% |
Historical Medians
Against its 10-year medians, its P/S is 22.0% above 5.9x and its P/B is 5238.5% above 3.9x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 7.2x | 6.6x | 5.9x |
| P/B | 208.2x | 23.4x | 3.9x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 3.4x in 2019 to 8.2x in 2021.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $38.21 | 42.5x | 7.3x | 30.0x |
| 2024 | $17.42 | N/A | 5.9x | 24.5x |
| 2023 | $8.99 | N/A | 3.9x | 3.4x |
| 2022 | $21.03 | N/A | 7.2x | 31.5x |
| 2021 | $31.04 | N/A | 8.2x | 6.3x |
| 2020 | $27.26 | N/A | 6.5x | 6.6x |
| 2019 | $14.20 | N/A | 3.4x | 2.8x |
| 2018 | $22.63 | N/A | 5.6x | 2.9x |
| 2017 | $21.07 | N/A | 5.3x | 2.9x |
| 2016 | $18.93 | N/A | 5.3x | 2.4x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TVTX
What is TVTX's forward P/E ratio?
Travere Therapeutics has a forward P/E ratio of 25.1x.
Is TVTX stock overvalued?
GNG's valuation label for TVTX is Undervalued.
What is TVTX's price to sales ratio?
Travere Therapeutics has a price to sales ratio of 7.2x.
TVTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts